Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > BUSINESS
BUSINESS
- Shionogi, Eli Lilly Japan Announce Add’l Indication of DNP for Cymbalta
February 22, 2012
- IBL: ADAMTS5 Test Kit for Predicting Efficacy of Biologic Treatments in RA
February 22, 2012
- Glivec Receives Add’l Indication for HES/CEL: Novartis Pharma
February 22, 2012
- Cellectis of France Surrenders Claim for Damages Against Shionogi
February 22, 2012
- DSP Obtains Approval for Myslee Generic, Boosting Efforts to Strengthen CNS Field
February 21, 2012
- Pfizer Japan, DSP Apply for Pediatric Indication for Norvasc and Amlodin Based on Data from Public Domain
February 21, 2012
- Astellas, SKK Announce Alliance in Field of Kidney Diseases
February 21, 2012
- Nichi-Iko Makes Yakuhan Subsidiary to Expand Disinfectant Lineup
February 21, 2012
- Kowa Launches Livalo in Mexico through Eli Lilly
February 21, 2012
- Sales of DPP-4 Inhibitors Reach ¥100 Billion Level, Antidiabetic Drugs Show Double-Digit Growth: IMS Japan
February 20, 2012
- Pfizer Japan Ranked No. 1 as Promotion Company: IMS Japan
February 20, 2012
- Qol President Nakamura Says “Proactive Cooperation” Needed for Distribution Improvement
February 20, 2012
- Diabetes Treatments: Their Development and Market
February 20, 2012
- With Upcoming Price Cuts, Nursing Homes Present Opportunity for Makers of Generic AD Treatments
February 20, 2012
- Fuso Acquires Exclusive Domestic Marketing Rights to Mucus Bulging Agent
February 20, 2012
- Daiichi Sankyo, Roche Announce Approval of Malignant Melanoma Treatment Vemurafenib in EU
February 20, 2012
- 6 SGLT-2 Inhibitors in Final Development Stage, Applications Expected in 2013
February 17, 2012
- Qol Expects to Clear “30%” Generic Dispensing Mark Around October
February 17, 2012
- 40% of Doctors Prescribe Existing Drugs Until New Drug Information Is Clarified: Survey
February 17, 2012
- Daiichi Sankyo, Pfizer Obtain Approval for Their Competition Generics for June Listing
February 17, 2012
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…